Osaka, Japan-based Takeda Pharmaceuticals entered into a strategic collaboration with Teaneck, N.J.-based NuBiyota for its microbial ecosystem therapeutic products.
Here's what you should know.
1. Takeda and NuBiyota are collaborating on oral microbial consortia products, which NuBiyota will develop.
2. Takeda will pay NuBiyota an upfront payment as well as several developmental, regulatory, commercial and sales-based incentives.
3. Takeda recently entered into a similar agreement with Finch Therapeutics over its inflammatory bowel disease treatment.